Cited by 104Cardiac Ischemia and ReperfusionPeroxisome Proliferator-Activated ReceptorsCardiac Fibrosis and Remodeling

Pioglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, Attenuates Myocardial Ischemia/Reperfusion Injury in a Rat Model

Open access
Ito, Haruyasu, Nakano, Atsushi, Kinoshita, Makoto, Matsumori, Akira·2003·Laboratory Investigation

Abstract

Thiazolidinediones are insulin-sensitizing drugs, ligands for peroxisome proliferator-activated receptor-gamma (PPAR-gamma), which play an important role in the modulation of inflammatory responses. Myocardial ischemia/reperfusion (MI/R) injury is associated with inflammation, in which various cells, particularly monocytes and macrophages, are involved. This study examined the effects of the thiazolidinedione peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in a rat model of MI/R injury. Pioglitazone at 3 mg/kg/day or the vehicle was administered for 7 days before rats were subjected to 30 minutes of coronary ligation followed by 24 hours of reperfusion. The mRNA expression [monocyte chemoattractant protein-1 (MCP-1) and intercellular adhesion molecule-1] in the ischemic region, the number of infiltrating macrophages in the ischemic region, and the myocardial infarct size were examined. The inhibitory effects of pioglitazone on activated macrophages were studied in vitro. Phorbol 12-myristate 13-acetate-induced MCP-1 production, in the absence or presence of pioglitazone, were assayed in cultured macrophages. Compared with the control group, (1). mRNA levels of MCP-1 and intercellular adhesion molecule-1 and the number of infiltrating macrophages in the ischemic region were significantly lower in the pioglitazone-treated group; and (2). myocardial infarct size was significantly smaller in the pioglitazone-treated group. Phorbol 12-myristate 13-acetate-stimulated cultured macrophages in the presence of pioglitazone produced significantly lower levels of MCP-1 than the stimulated control in the absence of pioglitazone. These observations demonstrate that pioglitazone has anti-inflammatory effects in MI/R injury that are independent of its insulin-sensitizing effect.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.lab.0000106724.29121.da

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies in nondiabetic rats have shown a positive benefit of TZD treatment upon ischemia/reperfusion, although this has not been shown to be true for other models such as pigs.

    “Studies in nondiabetic rats have also shown a positive benefit of TZD treatment upon ischemia/reperfusion (158, 176, 390), although this has not been shown to be true for other models such as pigs (380).”

    From Cardiac remodeling in obesity (2008) · cites this paper as [158]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ito, H., Nakano, A., Kinoshita, M., & Matsumori, A.
Affiliations
Kyoto University (JP)
Corresponding author
Matsumori, Akira
Venue
Laboratory Investigation
Publisher
Elsevier BV
Published
2003-12
Volume
83
Issue
12
Pages
1715-1721
ISSN
0023-6837 (ISSN-L)
OpenAlex
W2019235722
Cited by
104
References
36
Citations by year
2025: 3 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 1 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 6 · 2014: 4 · 2013: 6 · 2012: 2
FWCI
6.34
Type
journal article
Language
en
Open access
Locations
  • Laboratory Investigation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Cardiac Ischemia and Reperfusion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
Keywords
pioglitazone, PPARγ agonists, thiazolidinediones, myocardial ischemia-reperfusion injury, myocardial infarct size, macrophage infiltration, MCP-1, ICAM-1, inflammation, anti-inflammatory activity, coronary artery ligation
MeSH terms
Pioglitazone, Animals, Disease Models, Animal, Hypoglycemic Agents, Macrophage Activation, Macrophages, Male, Myocardial Infarction, RNA, Messenger, Tetradecanoylphorbol Acetate, Transcription Factors, Myocardial Reperfusion Injury, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Intercellular Adhesion Molecule-1, Chemokine CCL2, Thiazolidinediones, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review